重组人血管内皮抑制素注射液联合体部伽马刀治疗中晚期肺癌的临床效果  

Clinical effect of Recombinant Human Endostatin Injection combined with gamma knife in the treatment of advanced lung cancer

作　　者：吴志瑛 魏刚刚 聂加康 WU Zhiying;WEI Ganggang;NIE Jiakang(Department of Tumor Radiotherapy,Nanchang 334 Hospital,Jiangxi Province,Nanchang330000,China;Department of Medical Oncology,Nanchang 334 Hospital,Jiangxi Province,Nanchang330000,China)

机构地区：[1]南昌三三四医院肿瘤放疗科,江西南昌330000 [2]南昌三三四医院肿瘤内科,江西南昌330000

出　　处：《中国当代医药》2023年第23期100-103,共4页China Modern Medicine

基　　金：江西省卫生健康委科技计划项目(20204094)。

摘　　要：目的研究重组人血管内皮抑制素注射液联合体部伽马刀治疗中晚期肺癌的临床效果。方法选取南昌三三四医院2019年4月至2021年4月经病理组织学或细胞学确诊的60例中晚期肺癌患者作为研究对象,采取随机数字表法分为A组和B组,每组30例。A组患者采用单纯立体定向伽马刀治疗,B组采用重组人血管内皮抑制素注射液联合体部伽马刀治疗。比较两组中晚期肺癌患者的炎症因子指标、肺功能指标、不良事件总发生率、生活质量评分、总体客观有效率及随访1年后的死亡率。结果B组患者治疗后第1、2、5天的血清C反应蛋白、白细胞介素-6水平均低于A组,差异有统计学意义(P<0.05)。B组患者治疗后的用力肺活量(FVC)、第1秒用力呼气容积(FEV1)和呼气峰值流速(PEF)均高于A组,差异有统计学意义(P<0.05)。B组患者的不良事件总发生率低于A组,差异有统计学意义(P<0.05)。B组患者治疗后生理、心理、环境、社会关系的生活质量评分均高于A组,差异有统计学意义(P<0.05)。B组患者的总体客观有效率高于A组,差异有统计学意义(P<0.05)。B组患者随访1年后的死亡率低于A组,差异有统计学意义(P<0.05)。结论重组人血管内皮抑制素注射液联合体部伽马刀治疗中晚期肺癌的临床价值更佳,不仅有利于加快病情恢复,提升生活质量,还有助于改善炎症因子水平与肺功能,且随访效果较好,属于临床更为有效的治疗方案。Objective To study the clinical effect of Recombinant Human Endostatin Injection combined with gamma knife in the treatment of advanced lung cancer.Methods A total of 60 patients with advanced lung cancer diagnosed by histopathology or cytology from April 2019 to April 2021 in Nanchang 334 Hospital were selected as the study subjects,they were randomly divided into Group A and Group B using a random number table method,with 30 cases in each group.Group A were treated with stereotactic gamma knife alone,Group B were treated with gamma knife combined with Recombinant Human Endostatin Injection.The inflammatory factor indicators,lung function indicators,total incidence of adverse events,quality of life scores,overall objective response rate and mortality rate after 1 year of follow-up were compared between two groups of advanced lung cancer patients.Results The serum C-reactive protein and interleukin-6 level in Group B were lower than those in Group A on the first,second and fifth days after treatment,the differences were statistically significant(P<0.05).After treatment,the forced vital capacity(FVC),forced expiratory volume in the first second(FEV1)and peak expiratory flow rate(PEF)of patients in Group B were higher than those in Group A,the differences were statistically significant(P<0.05).The total incidence of adverse events in Group B patients was lower than that in Group A,the difference was statistically significant(P<0.05).The quality of life scores of Group B patients in terms of physiology,psychology,environment and social relationships after treatment were higher than those of Group A,the differences were statistically significant(P<0.05).The overall objective effectiveness rate of Group B patients was higher than that of Group A,the difference was statistically significant(P<0.05).The mortality rate of Group B patients after 1 year of follow-up was lower than that of Group A,the difference was statistically significant(P<0.05).Conclusion Recombinant Human Endostatin Injection combined with gamma knife

关 键 词：重组人血管内皮抑制素注射液 体部伽马刀 中晚期肺癌 临床研究 

分 类 号：R734.2[医药卫生—肿瘤]